Download PDF
Diabetologie und Stoffwechsel 2015; 10(05): R67-R84
DOI: 10.1055/s-0035-1553872
DuS-Refresher
© Georg Thieme Verlag KG Stuttgart · New York

Aktueller Stand der Insulinpumpentherapie

T. Siegmund
1   Städt. Klinikum München GmbH, Klinikum Bogenhausen, München
,
A. Thomas
2   Medtronic GmbH, Meerbusch
› Author Affiliations
Further Information

Publication History

Publication Date:
03 November 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Insulinpumpentherapie (CSII) ist die bedarfsgerechteste Form der Insulinzufuhr. Patienten mit Typ-1-Diabetes profitieren besonders von einer Verbesserung des HbA1c-Werts, der Abnahme von Hypoglykämien und geringeren Glukoseschwankungen. Nachweislich verringert das das Risiko für diabetische Folgeerkrankungen. Durch die Kopplung von Insulinpumpen mit dem kontinuierlichen Glukosemonitoring (CGM) zur Sensorunterstützten Pumpentherapie (SuP) werden die Vorteile dieser Form der Insulinabgabe noch deutlicher. Damit ist auch ein erster Schritt zu einem geschlossenen System erfolgt. In diesem Artikel geht es um eine Darstellung von CSII und SuP und den Beleg ihrer Wirksamkeit.

Abstract

Insulin pump therapy (CSII) is the most physiological form of insulin delivery. Patients with type 1 diabetes benefit from an improvement in HbA1c, reduction of hypoglycemic episodes and reduced glucose fluctuations. There is clear evidence that this reduces the risk of long term diabetic complications. By coupling an insulin pump with a continuous glucose monitoring system (CGM) to a sensor-augmented pump therapy (SAP), the advantages of this kind of insulin delivery becomes even more apparent. Thus, a first step toward a closed loop system has been made. This article describes and highlights CSII and SAP and presents evidence of their effectiveness.

 

  • Literatur

  • 1 Hepp KD, Renner R, Funcke HJ et al. Glucose homeostasis under continuous intravenous insulin therapy in diabetics. Horm Metab Res 1977; (Suppl. 07) 72-76
    Google Scholar
  • 2 Pickup JC, Keen H, Parsons JA et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1978; 1: 204-207
    CrossrefGoogle Scholar
  • 3 Pickup JC, Keen H, Parsons JA et al. Continuous subcutaneous insulin infusion: good blood glucose control for up to 4 days. Diabetologia 1979; 16: 385-389
    CrossrefGoogle Scholar
  • 4 Mecklenburg RS, Benson JW, Becker NM et al. Clinical use of the insulin infusion pump in 100 patients with type 1 diabetes. N Engl J Med 1982; 307: 513-518
    CrossrefGoogle Scholar
  • 5 Koivisto VA, Yki-Jarvinen H, Helve E et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986; 35: 78-82
    CrossrefGoogle Scholar
  • 6 Chantelau E, Spraul M, Mühlhauser I et al. Long-term safety, efficacy and side effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989; 32: 421-426
    CrossrefGoogle Scholar
  • 7 Linkeschova R, Raoul M, Bott U et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002; 19: 746-751
    CrossrefGoogle Scholar
  • 8 Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19: 324-327
    CrossrefGoogle Scholar
  • 9 Boland EA, Grey M, Oesterle A et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779-1784
    CrossrefGoogle Scholar
  • 10 Maniatis AK, Klingensmith GJ, Slover RH et al. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001; 107: 351-356
    CrossrefGoogle Scholar
  • 11 Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J 1985; 290: 811-815
    CrossrefGoogle Scholar
  • 12 Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J 1986; 293: 1195-1199
    CrossrefGoogle Scholar
  • 13 Lüddeke HJ, Hofmann W, Guder WG et al. Urinary albumin concentration in 52 CSII treated type 1 diabetic patients during a follow-up of 4 years. Diabetes und Stoffwechsel 2002; 11 (Suppl. 01) 115
    Google Scholar
  • 14 Aragona M, Giannarelli R, Coppelli A et al. Improvement of retinopathy in type 1 diabetic patients treated with continuous subcutaneous insulin infusion (CSII). Diabetes Metabol 2003; 29: 4S235
    Google Scholar
  • 15 Danne T, von Schütz W, Lange K et al. Current practice of insulin pump therapy in children and adolescents – the Hannover recipe. Pediatr Diabetes 2006; 7 (Suppl. 04) 25-31
    PubMedGoogle Scholar
  • 16 Danne T, Lange K, Kordonouri O. New developments in the treatment of type 1 diabetes in children. Arch Dis Child 2007; 92: 1015-1019
    CrossrefGoogle Scholar
  • 17 Kordonouri O, Hartmann R, Lauterborn R et al. Age-specific advantages of continuous subcutaneous insulin infusion as compared with multiple daily injections in pediatric patients. Diabetes Care 2006; 29: 133-134
    CrossrefPubMedGoogle Scholar
  • 18 Vortherms J, Klinkert C, Lotz N et al. Insulinpumpentherapie bei Kindern und Jugendlichen mit schwerwiegenden Verhaltensauffälligkeiten. Diabetes und Stoffwechsel 2001; 10 (Suppl. 01) 56
    Google Scholar
  • 19 Knight S, Northam E, Donath S et al. Improvements in cognition, mood and behaviour following commencement of continuous subcutaneous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study. Diabetologia 2009; 52: 193-198
    CrossrefGoogle Scholar
  • 20 Berghaeuser MA, Kapellen T, Heidtmann B et al. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes 2008; 9: 590-595
    CrossrefGoogle Scholar
  • 21 Holder M, Ludwig-Seibold C, Lilienthal E et al. Trends in der Insulinpumpentherapie bei Kindern, Jugendlichen und jungen Erwachsenen mit Typ-1-Diabetes von 1995–2006: Daten der DPV-Initiative. Diabetologie & Stoffwechsel 2007; 2: 169-174
    Google Scholar
  • 22 Chase HP, Saib SZ, MacKenzie T et al. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. Diabet Med 2002; 19: 317-321
    CrossrefGoogle Scholar
  • 23 Gross TM, Kayne D, King A et al. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 2003; 5: 365-369
    CrossrefGoogle Scholar
  • 24 Danne T, Reichel A, Liebl A et al. First user experience with an integrated insulin pump and real-time continuous glucose monitoring system in German patients with type 1 diabetes. Diabetes 2006; 55 (Suppl. 01) A194-A195
    Google Scholar
  • 25 Ly TT, Nicholas JA, Retterath A et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy in patients with type 1 diabetes. A randomized clinical trial. JAMA 2013; 310: 1240-1247
    CrossrefGoogle Scholar
  • 26 Danne T, Tsioli C, Kordonouri O et al. The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise. Diabetes Technol Ther 2014; 16: 338-347
    CrossrefGoogle Scholar
  • 27 Dehais J, Anthimopoulos M, Shevchik S et al. A prototype system for carbohydrate content estimation based on computer vision method. Diabetes Technol Ther 2014; 16 (Suppl. 01) A108-A109
    Google Scholar
  • 28 Hilderbrandt P, Birch K, Jensen FM et al. Absorption of subcutaneously infused insulin: influence of basal rate pulse interval. Diabetes Care 1985; 8: 287-290
    CrossrefGoogle Scholar
  • 29 Heinemann L, Nosek L, Kapitza C et al. Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care 2009; 32: 1437-1439
    CrossrefGoogle Scholar
  • 30 Pankowska E, Blazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther 2012; 14: 16-22
    CrossrefGoogle Scholar
  • 31 Jones SM, Quarry JL, Caldwell-McMillan M et al. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Ther 2005; 7: 233-240
    CrossrefGoogle Scholar
  • 32 Kordonouri O, Hartmann R, Remus K et al. Benefit of supplementary fat plus protein counting as compared with conventional carbohydrate counting for insulin bolus calculation in children with pump therapy. Pediatr Diabetes 2012; 13: 540-544
    CrossrefPubMedGoogle Scholar
  • 33 Shashaj B, Busetto E, Sulli N. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 2008; 25: 1036-1042
    CrossrefGoogle Scholar
  • 34 Ziegler R, Cavan DA, Cranston I et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care 2013; 36: 3613-3619
    CrossrefGoogle Scholar
  • 35 Siegmund T, Kolassa R, Thomas A. Sensorunterstützte Therapie (SuP) und Sensorunterstützte Pumpentherapie (SuP). Bremen: Unimed Science; 2011
    Google Scholar
  • 36 Bergenstal RM, Klonoff DC, Garg SK et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-232
    CrossrefGoogle Scholar
  • 37 Danne T, Kordonouri O, Remus K et al. Prevention of hypoglycaemia by using low glucose suspend (LGS) function in sensor-augmented pump therapy. Diabetes Technol Ther 2011; 13: 1129-1134
    CrossrefPubMedGoogle Scholar
  • 38 Buckingham BA, Cobry E, Clinton P et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009; 11: 93-97
    CrossrefPubMedGoogle Scholar
  • 39 Zecchin C, Facchinetti A, Sparacino G et al. Reduction of number and duration of hypoglycemic events by glucose prediction methods: a proof-of-concept in silico study. Diabetes Technol Ther 2013; 15: 66-77
    CrossrefGoogle Scholar
  • 40 Rudolph JW, Hirsch IB. Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocr Pract 2002; 8: 401-405
    CrossrefGoogle Scholar
  • 41 Hoogma RPL, Hammond PJ, Gomis R et al. on behalf of the 5-Nations Study Group Comparison of the effects continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2005; 23: 141-147
    Google Scholar
  • 42 Doyle EA, Weinzimer SA, Steffen AT et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injection using insulin glargine. Diabetes Care 2004; 27: 1554-1558
    CrossrefGoogle Scholar
  • 43 Heptulla RA, Allen HF, Gross TM et al. Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy. Pediatr Diabetes 2004; 5: 10-15
    CrossrefGoogle Scholar
  • 44 Pickup JC, Kidd J, Burmiston D et al. Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes. Pract Diabetes Int 2005; 22: 10-14
    CrossrefGoogle Scholar
  • 45 Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087
    CrossrefGoogle Scholar
  • 46 Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51: 941-951
    CrossrefGoogle Scholar
  • 47 Pickup J, Sutten AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-774
    CrossrefGoogle Scholar
  • 48 The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial (DCCT). Diabetes 1997; 46: 271-286
    CrossrefGoogle Scholar
  • 49 Bode B. Pump therapy. Diabet Med 2006; 23 (Suppl. 04) 426-427
    CrossrefGoogle Scholar
  • 50 Austenat E, Würzner M, Semmler S et al. CSII is superior to mdi for type 1 diabetes under real world conditions in clinical endpoints. Diabetes 2006; 55 (Suppl. 01) A459
    Google Scholar
  • 51 Steineck I, Cederholm J, Eliasson B et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. BMJ 2015; 350: h3234
    CrossrefGoogle Scholar
  • 52 Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. BMJ 2002; 324: 1-6
    CrossrefGoogle Scholar
  • 53 Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687
    CrossrefPubMedGoogle Scholar
  • 54 Ceriello A, Kumar S, Piconi L et al. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 2007; 30: 649-654
    CrossrefGoogle Scholar
  • 55 Monnier L, Colette C, Leiter L et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007; 30: 185-186
    Google Scholar
  • 56 Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J Diabetes Complications 2005; 19: 178-181
    CrossrefGoogle Scholar
  • 57 Schreiver C, Jacoby U, Thomas A et al. Glycaemic variability in paediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): a cross-sectional cohort study. Clin Endocrinol 2013; 79: 641-647
    Google Scholar
  • 58 Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598
    CrossrefGoogle Scholar
  • 59 Lauritzen T, Pramming S, Deckert T et al. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24: 326-329
    Google Scholar
  • 60 Heise T, Nosek L, Biilmann Ronn B et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620
    CrossrefGoogle Scholar
  • 61 Liebl A, Krinelke L. Long-term results of insulin pump therapy (CSII) in adolescents and adults with type 1 diabetes mellitus in Germany. Diabetologia Polska 2003; 10: 179-185
    Google Scholar
  • 62 EQuality1 Study Group – Evaluation of QUALITY of Life and Costs in Diabetes Type 1. Quality of life and treatment satisfaction in adults with Type 1 diabetes. A comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008; 25: 213-220
    CrossrefGoogle Scholar
  • 63 Schottenfeld-Naor Y, Galatzer A, Karp M et al. Comparison of metabolic and psychological parameters during continuous subcutaneous insulin infusion and intensified conventional insulin treatment in type I diabetic patients. Isr J Med Sci 1985; 21: 822-828
    Google Scholar
  • 64 Shapiro J, Wigg D, Charles MA et al. Personality and family profiles of chronic insulin-dependent diabetic patients using portable insulin infusion pump therapy: a preliminary investigation. Diabetes Care 1984; 7: 137-142
    CrossrefGoogle Scholar
  • 65 Cyganek K, Hebda-Szydlo A, Katra B et al. Efficacy and safety of continuous subcutaneous insulin infusion therapy in pregnancy complicated by type 1 diabetes. Diabetes 2009; 58 (Suppl. 01) A466-A467
    Google Scholar
  • 66 Cyganek K, Katra B, Skupien J et al. Glycemic control and selected pregnancy outcomes in type 1 diabetes women on continuous subcutaneous insulin infusion and multiple daily injections: the significance of pregnancy planning. Diabetes Technol Ther 2010; 12: 41-47
    CrossrefGoogle Scholar
  • 67 Jovanovic L, Knopp RH, Kim H et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 2005; 28: 1113-1117
    CrossrefGoogle Scholar
  • 68 Herman WH, Ilag LL, Johnson SL et al. Clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28: 1568-1573
    CrossrefGoogle Scholar
  • 69 Raskin P, Bode BW, Marks JB et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. A randomized, parallel-group, 24-week study. Diabetes Care 2003; 26: 2598-2603
    CrossrefGoogle Scholar
  • 70 Reznik Y, Cohen O, Aronson R et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014; 384: 1265-1272
    CrossrefPubMedGoogle Scholar
  • 71 Hirsch IB, Abelseth J, Bode BW et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008; 10: 377-383
    CrossrefPubMedGoogle Scholar
  • 72 O’Connell MA, Donath S, O’Neal DN et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009; 52: 1250-1257
    CrossrefGoogle Scholar
  • 73 Raccah D, Sulmont V, Reznik Y et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes. Diabetes Care 2009; 32: 2245-2250
    CrossrefGoogle Scholar
  • 74 Bergenstal RM, Tamborlane WV, Ahmann A et al. for the STAR 3 Study Group Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. NEJM 2010; 363: 311-320
    CrossrefGoogle Scholar
  • 75 Hermanides J, Nørgaard K, Bruttomesso D et al. Sensor augmented pump therapy lowers HbA(1c) in suboptimally controlled type 1 diabetes: a randomised controlled trial. Diabet Med 2011; 28: 1158-1167
    CrossrefGoogle Scholar
  • 76 Battelino T, Conget I, Olsen B et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia 2012; 55: 3155-3162
    CrossrefGoogle Scholar
  • 77 Schaepelynck P, Rocher L, Hanaire H et al. Patient- or physician-driven Continuous Glucose Monitoring (CGM) improves control and Quality of Life (QoL) in poorly-controlled type 1 diabetic patients on intensified insulin therapy: A one-year multicenter study. Diabetes 2011; 60 (Suppl. 01) A65
    Google Scholar
  • 78 Ludwig-Seibold UC, Holder M, Rami B et al. Continuous glucose monitoring in children, adolescents, and adults with type 1 diabetes mellitus: analysis from the prospective DPV diabetes documentation and quality management system from Germany and Austria. Pediatr Diabetes 2011; 13: 12-14
    Google Scholar
  • 79 Choudhary P. Intelligence and convenience: now a reality with MiniMed 640G. Symposium Medtronic 19.02.2015 “The new frontier in artificial pancreas systems.” Paris: Congress Advanced Technologies & Treatments for Diabetes; 2015
    Google Scholar